The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rustomyan A.V.

Sechenov First Moscow State Medical University (Sechenov University)

Kondrashin S.A.

Sechenov First Moscow State Medical University (Sechenov University)

Fomin V.V.

Sechenov University

Therapy with original and generic forms of clopidogrel after implantation of Russian drug-eluting coronary stents

Authors:

Rustomyan A.V., Kondrashin S.A., Fomin V.V.

More about the authors

Journal: Russian Cardiology Bulletin. 2024;19(2): 62‑66

DOI: 10.17116/Cardiobulletin20241902162

Read: 1047 times

Download PDF (RU)
Contact the author
Table of contents

THERAPY WITH ORIGINAL AND GENERIC FORMS OF CLOPIDOGREL AFTER IMPLANTATION OF RUSSIAN DRUG-ELUTING CORONARY STENTS
THERAPY WITH ORIGINAL AND GENERIC FORMS OF CLOPIDOGREL AFTER IMPLANTATION OF RUSSIAN DRUG-ELUTING CORONARY STENTS

To cite this article:

Rustomyan AV, Kondrashin SA, Fomin VV. Therapy with original and generic forms of clopidogrel after implantation of Russian drug-eluting coronary stents. Russian Cardiology Bulletin. 2024;19(2):62‑66. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20241902162

 
ЭндоКард
Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

OBJECTIVE

To compare antiplatelet efficacy of original clopidogrel and its generic analogue after implantation of Russian drug-eluting stents.

MATERIAL AND METHODS

Considering ADP-induced platelet aggregation, we compared aggregation in 3 and 30 days after intake of original and generic clopidogrel.

RESULTS

After 3 days, ADP-induced platelet aggregation was 36.5% and 39.1%, after a month — 38.9% and 43.7%, respectively. There were no major cardiac events (cardiac death, non-fatal acute myocardial infarction, stroke, stent thrombosis, stent restenosis, repeated target vessel revascularization, recurrence or progression of angina pectoris) throughout 12-52 months after stenting.

CONCLUSION

We found no significant between-group difference in ADP-induced platelet aggregation and incidence of major cardiac events.

Keywords:

clopidogrel
generic analogue of clopidogrel
coronary stenting
ADP-induced aggregation
Russian drug-eluting stents

Authors:

Rustomyan A.V.

Sechenov First Moscow State Medical University (Sechenov University)

Kondrashin S.A.

Sechenov First Moscow State Medical University (Sechenov University)

Fomin V.V.

Sechenov University

Received:

16.08.2023

Accepted:

01.11.2023

Close metadata

References:

  1. Population Division. Department of Economic and Social Affairs. United Nations. Revision of World Population Prospects. https://esa.un.org/unpd/wpp/
  2. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New England Journal of Medicine. 1996;334:1084-1089.
  3. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018;39(3):213-260.  https://doi.org/10.1093/eurheartj/ehx419
  4. Elektronnyy sayt cpravochnik lekarstv po GRLS MinZdrava RF. (In Russ.).
  5. Zyryanov SK, Dumchenko EV. Analysis of the structure of consumption of antiplatelet drugs in the Russian pharmaceutical market: 2014—2016. Kachestvennaya Klinicheskaya Praktika. 2017;(2):29-34. (In Russ.).
  6. Andreeva AV, Filippov EV. Clopidogrel: original drug or generic? Doctor.Ru. 2020;19(11):17-21. (In Russ.). https://doi.org/10.31550/1727-2378-2020-19-11-17-21
  7. Alekyan BG, Grigor’yan AM, Staferov AV, Karapetyan NG. Endovascular diagnostics and treatment in the Russian Federation (2020). Russian Journal of Endovascular Surgery. 2021;8(Special Issue):S5-S248. (In Russ.).
  8. Serova NS, Kondrashina OS, Kondrashin SA. Volumetric dynamic 640-slice CT of coronary arteries. Medical Visualization. 2018;(4):32-39. (In Russ.). https://doi.org/10.24835/1607-0763-2018-4-32-39
  9. Sulimov VA, Moroz EV. Resistance to antiplatelet drugs (aspirin, clopidogrel) in patients undergoing elective percutaneous coronary intervention. Rational Pharmacotherapy in Cardiology. 2012;8(1):23-30. (In Russ.). https://doi.org/10.20996/1819-6446-2012-8-1-23-30
  10. Komarov AL, Panchenko EP. Platelet function test for the assessment of thrombosis and bleeding risk in chd patients taking antiplatelet medications. Russian Journal of Cardiology. 2015;3(119):25-34. (In Russ.).
  11. Sicras-Mainar A, Escobar-Cervantes C, Micó-Pérez RM, Llisterri-Caro JL. Consecuencias clínicas y económicas en pacientes que inician tratamiento con clopidogrel de marca vs. genérico: estudio retrospectivo de vida real. Semergen. 2020;46(1):16-26.  https://doi.org/10.1016/j.semerg.2019.05.004
  12. Dronova EP, Lopatin YuM. Clinical and economic analysis of the original and generic forms of clopidogrel in coronary heart disease after endovascular interventions. Good Clinical Practice. 2010;1:61-67. (In Russ.).
  13. Alekyan BG, Grigor’yan AM, Staferov AV, Karapetyan NG. Endovascular diagnostics and treatment in the Russian Federation (2017). Endovaskulyarnaya Khirurgiya (Russian Journal of Endovascular Surgery). 2018;2(5):93-240. (In Russ.).
  14. Leclerc J, Thibault M, Midiani Gonella J, Beaudoin C, Sampalis J. Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis. Drugs. 2020;80(7):697-710.  https://doi.org/10.1007/s40265-020-01296-x
  15. Hajizadeh R, Ghaffari S, Ziaee M, Shokouhi B, Separham A, Sarbakhsh P. In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris. Journal of Cardiovascular and Thoracic Research. 2017;9(4):191-195.  https://doi.org/10.15171/jcvtr.2017.33
  16. Skotnikov AS, Sizova ZM, Baglikov AN, Rozhnova OG, Novitsky NI. Comparison of the original (Plavix) and generic (Clapitax) clopidogrel on platelet aggregation: observational study. Russian Journal of Cardiology. 2018;(4):75-81. (In Russ.). https://doi.org/10.15829/1560-4071-2018-4-75-81
  17. Westphal ES, Aladeen T, Vanini D, Rainka M, McCadden K, Gengo FM, Bates V. Generic Clopidogrel: Has Substitution for Brand Name Plavix® Been Effective? Journal of Pharmacy Practice. 2022;35(4):536-540.  https://doi.org/10.1177/0897190021997006
  18. Wójcik T, Szymkiewicz P, Ściborski K, Łukaszewski M, Onisk G, Mysiak A, Gamian A, Wiśniewski J, Dobosz T, Lebioda A, Jonkisz A, Protasiewicz M. Original and generic clopidogrel: A comparison of antiplatelet effects and active metabolite concentrations in patients without polymorphisms in the ABCB1 gene and the allele variants CYPC19*2 and *3. Advances in Clinical and Experimental Medicine. 2021;30(5):485-489.  https://doi.org/10.17219/acem/133811
  19. Park YM, Ahn T, Lee K, Shin KC, Jung ES, Shin DS, Kim MG, Kang WC, Han SH, Choi IS, Shin EK. A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation. Korean Circulation Journal. 2012;42(7):458-463.  https://doi.org/10.4070/kcj.2012.42.7.458
  20. Patsourakos NG, Kouvari M, Kotidis A, Kalantzi KI, Tsoumani ME, Anastasiadis F, Andronikos P, Aslanidou T, Efraimidis P, Georgiopoulos A, Gerakiou K, Grigoriadou-Skouta E, Grigoropoulos P, Hatzopoulos D, Kartalis A, Lyras A, Markatos G, Mikrogeorgiou A, Myroforou I, Orkopoulos A, Pavlidis P, Petras C, Riga M, Skouloudi M, Smyrnioudis N, Thomaidis K, Tsikouri GE, Tsikouris EI, Zisimos K, Vavoulis P, Vitali MG, Vitsas G, Vogiatzidis C, Chantanis S, Fousas S, Panagiotakos DB, Tselepis AD. The incidence of recurrent cardiovascular events among acute coronary syndrome patients treated with generic or original clopidogrel in relation to their sociodemographic and clinical characteristics. The Aegean study. Archives of Medical Science. 2020;16(5):1013-1021. https://doi.org/10.5114/aoms.2020.95878
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.